Advancing Translational Models for Respiratory Infection Research
Case Study 1: Advancing Translational Models for Respiratory Infection Research
Challenge
A global pharmaceutical company sought to strengthen its preclinical understanding of bacterial lung infections following viral infection; an area associated with significantly increased patient risk. The objective was to develop robust laboratory models and generate insights to support therapeutic innovation.
Approach
We partnered closely with the client across multiple workstreams. This included the design and implementation of both in vitro and in vivo models to investigate host–pathogen interactions and evaluate potential host-directed therapies.
Our team developed a novel cell culture system to replicate key aspects of the pulmonary environment. Complementing this, we established in vivo models of viral lung infection and incorporating real-time bacterial infection tracking systems, enabling dynamic monitoring of disease progression.
In parallel, we provided analytical support on client-generated datasets and conducted a targeted literature review on the lung microbiome and relevant ex vivo modelling approaches.
Impact
This integrated programme delivered a suite of advanced, physiologically relevant models and actionable scientific insights. The work enhanced the client’s capability to evaluate therapeutic strategies and supported ongoing research in a complex and clinically significant disease area.
Supporting Preclinical Development of Wound Care Innovation
Case Study 2: Supporting Preclinical Development of Wound Care Innovation
Challenge
A mid-sized biotechnology company required robust preclinical evidence to evaluate the efficacy and safety of a novel wound healing and antimicrobial technology, with the goal of progressing towards early-stage clinical development.
Approach
We designed and implemented in vivo models to assess therapeutic performance in infected wound settings. Beyond measuring bacterial burden, our approach incorporated a comprehensive set of endpoints, including toxicity, wound healing progression, and the expression of key inflammatory biomarkers.
This multi-parameter framework enabled a holistic assessment of both efficacy and safety, aligned with translational and regulatory expectations.
Impact The project generated high-quality, decision-enabling data with both commercial and scientific value. These outcomes supported the client in advancing their programme towards first-in-human studies and strengthened the evidence base for future development and investment.